An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration.

MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma B.V.

Alexion Pharmaceuticals have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015.

Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel

Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100

Mesoblast has entered into an Agreement with Celgene

MorphoSys has regained rights to MOR202 from Celgene

Open Monoclonal Technology announced license that provides Celgene with unlimited access to OMT’s proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics

MedImmune and Joslin Diabetes Center announced a three-year research collaboration to develop new medicines for the treatment of diabetes, obesity, and related metabolic disorders

Blueprint Medicines announced a strategic collaboration with Alexion to discover, develop and commercialize novel drug candidates